DE-BIOCORP
1.10.2020 07:32:15 CEST | Business Wire | Press release
Regulatory News:
BIOCORP (Paris:ALCOR) (FR0012788065 - ALCOR / Eligible PEA PME), a French company specialized in the design, development and manufacture of innovative medical devices, today announced an alliance with Belgium-based AARDEX Group, the world leader in medication adherence solutions.
This alliance is to combine BIOCORP’s connected add-on solutions for drug delivery devices with AARDEX’s proprietary Medication Event Monitoring System (MEMS®) and offer a comprehensive solution to patients and healthcare providers to effectively measure and manage medication adherence. The financial terms of the agreement have not been disclosed, however the first initiative will be to integrate BIOCORP’s Injay connected solution for Pre-filled syringes (PFS) to AARDEX’s MEMS Adherence Software (MEMS AS® ), to target medicines delivered by PFS with potential applications in the field of Rheumatoid Arthritis, Multiple Sclerosis, Ophthalmology, Psoriasis or Cardiovascular diseases. The roadmap also includes integration with BIOCORP’s other connected devices, to cover further chronic conditions in the field of injectable, respiratory, and beyond.
David Dalla Vecchia, CEO and Financial Lead of AARDEX Group, said: "We are delighted to announce our partnership with BIOCORP. Our vision is to continuously innovate in data-driven medication adherence solutions to enhance digital therapeutics and patient empowerment. Partnering with BIOCORP - a true pioneer in connected devices - will significantly contribute to that objective and bring together a wealth of knowledge and experience to help meet the needs of today’s clinical trials, patients and healthcare providers.”
Éric Dessertenne, CEO of BIOCORP, concluded: “This collaboration with AARDEX Group brings a strong added value to our products and to our targeted users. Thanks to the integration with MEMS AS, a unique solution that analyzes deeply patient patterns and behaviors, we will go beyond just monitoring treatment adherence, by providing comprehensive and tailored solutions to boost patient’s engagement and effectively manage this issue. AARDEX specific expertise in clinical trials is also a strong asset and will enable us to create relationships with pharma companies right from the development stage of a drug”.
Medication adherence issues are well known by all healthcare stakeholders and its clinical and commercial impact have been quantified and heavily documented for many years now. The World Health Organization has stated that, in developed countries, adherence to long-term therapies in the general population is only around 50%. But this issue is not limited to commercialized drugs and real-life conditions, it also massively affects clinical trials, which impacts assessment of drug efficacy.
ABOUT AARDEX GROUP
AARDEX Group is the world leader in digital solutions to measure and manage medication adherence. Located in Belgium, in Switzerland and in the U.S., AARDEX develops and markets digital solutions for adherence-enhancing strategies in clinical trials, research settings, and professional healthcare systems. AARDEX is the central actor of a complete ecosystem that combines its MEMS® Adherence Software with a wide range of smart packages and devices that measure patient adherence across all routes of drug administration. Our vision is to continuously innovate in data-driven medication adherence solutions to enhance digital therapeutics and patient empowerment.
For more information, visit www.aardexgroup.com
ABOUT BIOCORP
Recognized for its expertise in the development and manufacture of medical devices and delivery systems, BIOCORP has today acquired a leading position in the connected medical device market thanks to Mallya. This intelligent sensor for insulin injection pens allows reliable monitoring of injected doses and thus offers better compliance in the treatment of diabetics. Available for sale from 2020, Mallya spearheads BIOCORP's product portfolio of innovative connected solutions. The company has 54 employees.
BIOCORP is listed on Euronext since July 2015 (FR0012788065 – ALCOR).
For more information, please visit www.biocorpsys.com
.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200930005883/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
The UAE’s Higher Colleges of Technology Celebrates Record Graduating Cohort of More Than 6,70010.11.2026 13:18:00 CET | Press release
Class of 2026 43% larger than the previous year as HCT expands applied and vocational educationHCT redesigns applied bachelor’s programmes to include a full year of workplace learning Higher Colleges of Technology (HCT) – one of the largest applied higher education institutions in the region – has celebrated its biggest graduating cohort to date, with more than 6,700 graduates from the 2025-2026 academic year, with the graduating cohort some 43% larger than the previous year’s. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261110846231/en/ More than 12,000 people attended HCT’s biggest graduating cohort to date (Photo: AETOSWire) More than 12,000 people gathered at Etihad Arena in Abu Dhabi for the ceremony, held under the theme “Strong Roots. Lasting Impact.”, in the presence of His Excellency Sheikh Nahyan bin Mubarak Al Nahyan, UAE Minister of Tolerance and Coexistence and founder of HCT. Also attending were His Excellen
FDA Approves Promega OncoMate® MSI Dx Analysis System as Companion Diagnostic for KEYTRUDA® in MSI-High Solid Tumors10.11.2026 13:00:00 CET | Press release
The U.S. Food and Drug Administration (FDA) has approved the Promega OncoMate® MSI Dx Analysis System designed to identify patients with microsatellite high (MSI-H) solid tumors as a companion diagnostic designed for KEYTRUDA®, Merck’s (known as MSD outside the U.S. and Canada) anti-PD-1 therapy. OncoMate® MSI Dx Analysis System is a PCR-based assay designed to evaluate MSI status in solid tumor tissue. MSI status can be used to inform treatment decisions and support precision oncology strategies. “This approval reflects our dedication to providing meaningful diagnostic advances, developed to the highest quality and regulatory standards,” says Alok Sharma, Global Clinical Market Director at Promega. “Our test connects patients with the therapy most likely to help them, working alongside our pharmaceutical collaborators and the clinicians who use the result.” This approval was supported through a collaboration with Merck, which markets KEYTRUDA®. Together, the companies are working to a
Component Sense Celebrates 25 Years With Over 80 Million Electronic Components Saved From Landfill10.11.2026 13:00:00 CET | Press release
Global electronics redistribution company marks its anniversary by planting 2,500 trees Component Sense, a global company specialising in the redistribution of excess and obsolete electronic components, has now saved over 80 million components from landfill. The milestone coincides with its 25th anniversary this November, which it is marking by planting 2,500 trees with One Tree Planted. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261110298637/en/ Kenny McGee, CEO and Founder, Component Sense The company redistributes excess components from Tier 1 original equipment manufacturers (OEMs) and electronics manufacturing services (EMS) providers to a global network of buyers, helping manufacturers recoup value from inventory that would otherwise go to waste. Excess inventory is both a financial and an environmental burden for electronics manufacturers. With lead times still running long, shortages and surpluses exist side by s
Suzano Publishes First Report Aligned With Taskforce on Nature-related Financial Disclosures Recommendations10.11.2026 12:18:00 CET | Press release
Report offers insight on Suzano’s ecosystem health impacts, risks and opportunities, and reinforces its nature strategy Suzano, the world’s largest pulp producer, has published its first report aligned with the recommendations of the Taskforce on Nature-related Financial Disclosures (TNFD). The TNFD reporting framework helps organizations identify and assess how their dependencies and impacts may generate nature and biodiversity related risks and opportunities, and to disclose how they are integrated into the company’s governance, strategy, and corporate management. Initially focused on Suzano’s direct Brazilian operations, the report establishes methodological foundations, strengthens internal capabilities, and creates a pathway for the gradual expansion of nature-related assessments and disclosures over the coming years. The report also reinforces Suzano’s Nature Strategy, launched in November 2025. As part of its ongoing commitment to stronger management and greater transparency reg
Robbyant Releases LingBot-Touch to Bring General-Purpose Touch Perception to Robots10.11.2026 10:23:00 CET | Press release
Robbyant, an embodied AI company within Ant Group, today announced the open-source release of LingBot-Touch, a tactile foundation model that gives robots a critical missing sense by enabling robust touch perception. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261109284905/en/ LingBot-Touch encodes magnetic tactile, visual tactile, and piezoresistive signals into unified tactile tokens for use by different action models. Pre-trained on nearly 5,000 hours of real-world tactile data, the model covers three mainstream sensing modalities—magnetic tactile, visual tactile, and piezoresistive sensing—and translates their diverse signals into a unified tactile representation. This allows different dexterous hands and action models to share and reuse tactile understanding, enabling robots to not only “see clearer” and “think deeper,” but also “feel sharper” during fine manipulation tasks, such as turning pages, unscrewing bottle ca
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom